$LLY

Eli Lilly's market value increased by approximately $36 billion in a single trading session, with shares holding gains near the upper range. A close at session highs could indicate sustained demand, potentially extending the move into the next session.

The Nasdaq Composite dropped 1.65% to 26,755.24, with the Russell 2000 falling to an RSI of 28.3. Gold and silver declined, while oil rose. RTX secured a $6.3B contract, Lockheed Martin unveiled a new interceptor, Eli Lilly shared trial data, and Alimentation Couche-Tard agreed to acquire retail assets from Irving Oil. IBM advanced in DARPA's Quantum Benchmarking Initiative.

Eli Lilly's phase 3 trial for retatrutide, a weight-loss drug, showed significant weight reduction (17.6% to 25%) and improvements in obesity-related conditions. The drug targets three hormone receptors. Eli Lilly plans to seek FDA approval, but no timeline is set. Unapproved versions of the drug have been linked to deaths, according to reports.

Eli Lilly's experimental weight loss drug, retatrutide, shows high efficacy in trials, but black market versions may have caused at least two deaths, according to FDA reports. The FDA and other agencies are likely to approve retatrutide this year. Black market GLP-1 drugs, including retatrutide, have been linked to severe complications, raising concerns about safety.

Eli Lilly (LLY) stock rose 3.3% to $1,205.24 on pipeline developments and pre-earnings positioning. A clinical trial collaboration with Prelude Therapeutics and a positive cancer drug spending report boosted sentiment. Analysts raised EPS estimates and reiterated Buy ratings. Institutional activity also increased. The S&P 500 and Nasdaq declined, highlighting Lilly's company-specific rally. Q3 2026 earnings are expected on October 29, with consensus EPS at $9.96.

Eli Lilly has started construction on a $6.5bn plant in Houston to produce Foundayo, its oral GLP-1 treatment for type 2 diabetes and obesity. The facility will create 600 jobs and is part of a $12.5m investment in workforce training. Foundayo is under regulatory review in over 40 countries, with a global rollout planned for 2027. This is the largest active pharmaceutical ingredient project in Texas history, according to Governor Greg Abbott.

Eli Lilly (LLY) saw $88.8M net ETF inflows on Oct. 12, extending a five-day buying streak. Top ETF buyers included SPY, SPYM, and IYH. LLY's trailing 12-month revenue is $79.67B, up 50.5% YoY, with a market cap of $1.10T. The stock trades at a P/E of 39.64.

Global cancer drug spending reached $252B in 2024 and is forecast to exceed $400B by 2028, with the U.S. accounting for 46%. Several companies, including Oncolytics Biotech (ONCY), Revolution Medicines (RVMD), Eli Lilly (LLY), Genmab (GMAB), and Exelixis (EXEL), are advancing treatments for colorectal and pancreatic cancers. Oncolytics reported accelerating enrollment in a colorectal cancer study, while Revolution Medicines received FDA approval for a pancreatic cancer drug.

NSW pharmacist and dietitian John Jones questioned Eli Lilly's direct-to-consumer platform, LillyDirect, which sells non-PBS listed medicines like Mounjaro. Jones, with 20 years of experience, owns three pharmacies and expressed concerns about the model.

Eli Lilly (LLY) shares fell 1.04% to $1,170.34, underperforming broader market indices. The company's stock has gained 3.9% over the past month. Analysts expect Q3 2026 EPS of $7.54 and revenue of $22.11B, up 7.41% and 25.59% YoY, respectively. Full-year estimates project EPS of $34.79 and revenue of $88.88B, up 43.7% and 36.37% YoY. LLY has a Zacks Rank of #3 (Hold) and a Forward P/E of 33.99.